This is the first long‐term study to show an effect on IgE concentrations in patients with asthma who were on ICS treatment at baseline, brought about simply by optimizing the anti‐inflammatory treatment (ICS and LTRA) according to FENO or symptoms. This evidence concerns the gene IGHE and asthma.